EPIDEMIOLOGY AND DIRECT HEALTH CARE COSTS OF DIABETIC RETINOPATHY- RESULTS FROM A POPULATION-BASED STUDY
Author(s)
Ciampichini R1, Cortesi PA1, Cozzolino P2, Fornari C1, Madotto F1, Chiodini V1, Mantovani LG3, Cesana G1
1University of Milano - Bicocca, Monza, Italy, 2Charta Foundation, Milan, Italy, 3Federico II University of Naples, Naples, Italy
OBJECTIVES The aim of this study was to assess the epidemiologic and economic burden of diabetic retinopathy (DR) in terms of incidence, treatment patterns and cost by a population-based study.METHODS Eligible patients were identified through a data warehouse (DENALI), which matches demographic, clinical and economic data of about 9.9 million individuals of Lombardy region. The study population consists of all individuals with a diagnosis of diabetes who, during the period 1-1-2000 to 31-12-2010 received one of the following healthcare services: hospital admission (HA) for diabetes with ophthalmic manifestations or retinal disorders, fluorescein angiography or angioscopy of eye, destruction of chorioretinal lesion, repair of retinal tear, injection of vitreous substitute, and repeated ophthalmic examinations. The study population was followed for a minimum of 1 to a maximum of 10 years. We evaluated demographic characteristics of the study population and costs from the National Health Service’s perspective.RESULTS The 2000-2010 DR population was estimated to be around 127,000 (52% male). The average incidence per year and the 2010-prevalence were 6.1 and 24.2 per 100 diabetic patients. Median age(min-max) at the index event was 68.6(0.3-104.4) with 37% younger than 65-years. Around 15% of the population had Charlson Comorbidity Index>=1 and the overall mortality was 41.8 deaths/100 patient-years. The 10-year mean cost for DR patients were 17,361€(95%C.I. 12,673-22,050) compared with 4,771€ in a control diabetic population without complications. HA costs represented the driver of total costs, ranging from 45% (index year) to 36% (last year of follow-up), followed by drug (30-34.4%) and outpatient (25-29.7%). During the index year 13% of HA and outpatient costs were attributed to eye-specialist departments. Approximately 1% received intravitreal injections in 2010. CONCLUSIONS This study attempted to describe the burden of DR in Italy revealing socio-economic aspects relevant in terms of incidence and costs.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PDB113
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders